Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-04
2007-12-04
Solola, Taofiq (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
11332998
ABSTRACT:
6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile substantially free of 2,3,7-triamino-4,6-dimethyl-1,9-phenazinedicarbonitrile, and the anhydrous monoacetate salt thereof, are useful in the treatment of alpha-2 mediated disorders such as ocular hypertension.
REFERENCES:
patent: 5478858 (1995-12-01), Cupps et al.
patent: 5541210 (1996-07-01), Cupps et al.
patent: 5691370 (1997-11-01), Cupps et al.
patent: 6066740 (2000-05-01), Godlewski et al.
patent: WO 95/16685 (1995-06-01), None
patent: WO 96/04270 (1996-02-01), None
patent: WO 98/23595 (1998-06-01), None
patent: WO 98/46595 (1998-10-01), None
patent: WO 99/26942 (1999-06-01), None
Bosch Gregory Kent
Curtis Michael David
Gibbs Richard Alan
Nikolaides Nicholas
Randall Jared Lynn
Greenlee Winner and Sullivan P.C.
Solola Taofiq
The Board of Regents of the University of Nebraska
LandOfFree
6-[(4,5-Dihydro-1H-imidazol-2-yl)amino]-7-methyl-1H-benzimid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino]-7-methyl-1H-benzimid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino]-7-methyl-1H-benzimid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3832102